

# ASX Announcement



Medibio Limited – 21 September 2022

## CLOSING DATE FOR DIRECTOR NOMINATIONS

**Melbourne, Australia and Minneapolis, MN – 21 September 2022: Medibio Limited (MEB or the Company)** (ASX: MEB) (OTCPINK: MDBIF) advises in accordance with ASX Listing Rule 3.13.1 and Clause 3.5 of the Company's Constitution, that its Annual General Meeting will be held on Friday, 11 November 2022.

The closing date for receipt of nominations for election for Directors is Friday, 30 September 2022. Any nominations must be received no later than 5.00pm (AEST) on this date at the Company's registered office.

The Company notes that the deadline for nominations for the position of Director is separate to voting on Director elections. Details of the Directors to be elected will be included in the forthcoming Notice of AGM.

**ENDS**

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

### For Further information:

Mathew Watkins  
Company Secretary  
T: +61 3 9692 7222

### About

### Medibio

### Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).